Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Revelation Biosciences advances its Gemini acute kidney injury program toward the Phase 2/3 TITAN study after selecting Avance Clinical to support pivotal trial execution and hospital-based patient recruitment. Representative image.
Pharma & Biotech

Revelation Biosciences has its CRO for TITAN. Now Gemini faces the acute kidney injury test that really matters

Revelation Biosciences names Avance Clinical for the Phase 2/3 TITAN study as Gemini approaches its pivotal acute kidney injury test.

Read More
FairJourney Bio’s antibody engineering work is advancing a tumor-conditional IL-12 approach designed to activate potent cytokine signaling more selectively within the tumor microenvironment, potentially addressing one of IL-12 therapy’s longstanding toxicity challenges. Representative image.
Pharma & Biotech

Can FairJourney Bio’s reversible antibody switch solve IL-12’s decades-old toxicity problem?

FairJourney Bio engineers a tumor-conditional IL-12 switch designed to limit systemic exposure and localize cytokine activation in solid tumors.

Read More
Tolerance Bio’s license for NeoImmuneTech’s clinical-stage long-acting interleukin-7 therapy efineptakin alfa strengthens its push into thymic function and immune-resilience research, bringing an established human-stage asset into its emerging thymus-focused pipeline. Representative image.
Pharma & Biotech

Tolerance Bio has found a faster route into the clinic, but can efineptakin alfa protect thymic function?

Tolerance Bio licenses efineptakin alfa from NeoImmuneTech, adding clinical-stage IL-7 to its thymus and immune-resilience strategy.

Read More
NTx Bio’s RNA manufacturing technology supports Baylor College of Medicine’s production workflow for Diakonos Oncology’s DOC1021 personalized cancer vaccine in a Phase 1/2 refractory melanoma trial, highlighting the manufacturing challenge behind patient-specific cancer immunotherapies. Representative image.
Pharma & Biotech

NTx Bio supports Baylor manufacturing for Diakonos Oncology’s DOC1021 Phase 1/2 melanoma trial

NTx Bio enters the DOC1021 manufacturing workflow as Diakonos tests a personalized dendritic cell therapy in refractory melanoma.

Read More
Zipalertinib Phase 3 REZILIENT3 data are set for WCLC 2026 as attention turns to whether the first-line combination can strengthen treatment options for EGFR exon 20 insertion-positive non-small cell lung cancer. Representative image.
Pharma & Biotech

Taiho Oncology and Cullinan Therapeutics prepare pivotal zipalertinib data for WCLC 2026

Zipalertinib’s pivotal REZILIENT3 data will debut at WCLC 2026 after the first-line lung cancer trial met its PFS endpoint.

Read More
IntraBio’s pivotal Phase III CACNA1A trial is enrolling patients as levacetylleucine moves into a key clinical test, with recruitment expected to be completed in October 2026. Representative image.
Pharma & Biotech

What IntraBio’s IB1001-304 Phase III trial could reveal about CACNA1A treatment

IntraBio’s Phase III CACNA1A trial is enrolling, with October recruitment completion targeted as levacetylleucine enters a pivotal test.

Read More
GenBio AI’s human cell world model aims to bring genomics, proteins, cellular morphology and AI-driven simulation into a single virtual biology framework, potentially helping researchers test drug and genetic interventions before moving promising hypotheses into the wet lab. Representative image.
Pharma & Biotech

Can AI simulate a human cell before the wet lab? GenBio AI says its world model brings the idea closer

GenBio AI has unveiled a virtual cell world model spanning biological scales. See what it can simulate and what still needs validation.

Read More
VectorBuilder and Lir Therapeutics are combining AAV capsid engineering, AI-guided design and translational development capabilities as they seek to narrow the gap between promising gene therapy vectors and clinically viable candidates. Representative image.
Pharma & Biotech

What the VectorBuilder and Lir Therapeutics alliance means for next-generation gene therapy vectors

VectorBuilder and Lir Therapeutics are linking AI-guided AAV capsid design with translational development to tackle gene therapy delivery barriers.

Read More
A representative image illustrating Regeneron Pharmaceuticals’ Pasatru approval as the FDA clears the new fibrodysplasia ossificans progressiva treatment after Phase 3 data showed a 90% reduction in new heterotopic ossification lesions.
Pharma & Biotech

FDA clears monthly Pasatru after Phase 3 data show sharp drop in abnormal bone formation

FDA approves Regeneron’s Pasatru after Phase 3 data showed a 90% reduction in new FOP bone lesions. See what the new therapy means.

Read More
A representative image illustrating Teva Pharmaceutical Industries’ ecopipam program as the FDA grants Priority Review for the investigational pediatric Tourette syndrome treatment following positive Phase 3 relapse-prevention data.
Pharma & Biotech

Teva’s ecopipam reaches FDA Priority Review after positive Phase 3 Tourette data

FDA grants Priority Review to Teva’s ecopipam after Phase 3 data showed a 53% lower Tourette relapse risk. See what the 2027 decision could mean.

Read More